Table 3.
A list of recent clinical trials of nanomedicines for the treatment of selected solid tumors.
| Particle Type/Therapeutic Agent | Treatments | Cancer Subtypes | Trial Starting Date | Phase | Aim of the Study | NCT Number |
|---|---|---|---|---|---|---|
| ABI-009 (nab-Rapamycin) | Combination therapy | GBM | Aug. 2018 | II | ABI-009 will be tested as single agent or in combination with standard therapies | NCT03463265 |
| Abraxane® | Combination therapy | pancreatic ductal adenocarcinoma (PDA) | Jul. 2018 | II | To compare the first-line treatment with nab-PTX plus S-1 and nab-PTX plus GEM in advanced PDA with primary tumor nonexcision in Chinese patients | NCT03636308 |
| Abraxane® | Combined with CPT | HER-2 Negative BC | Nov. 2018 | IV | To evaluate of the efficacy and safety of nanoparticle albumin-bound PTX combined with CPT as neoadjuvant chemotherapy in luminal B/HER-2 negative BC | NCT03799692 |
| Abraxane® | Combined with Epirubicin and Cyclophosphamide | TNBC | Nov. 2018 | IV | To evaluate of the efficacy and safety of weekly Nab-P followed by dose-intensive epirubicin in combination with cyclophosphamide as neoadjuvant chemotherapy in TNBC | NCT03799679 |
| Pegylated liposomal DOX (PLD) | Combined with trastuzumab | HER2-positive BC | Mar. 2019 | II | To evaluate the efficacy and safety of PLD in combination with trastuzumab in HER-2 positive metastatic BC | NCT03933319 |
| Pegylated Liposomal DOX (Doxil/Caelyx) | Combined with pembrolizumab (Keytruda) | Metastatic Endocrine-resistant BC (ERBC) | Apr. 2019 | I/II | To evaluate the tumor response and appropriate dose of a chemo-immunotherapy regime consisting of treatment with PLD and pembrolizumab-based in ERBC patients | NCT03591276 |
| QDs coated with veldoreotide | Monotherapy | BC | Sep. 2019 | I | A novel formulation for treatment and bioimaging of BC which can deliver safely to the patients in a high dose to the affected tumor cells | NCT04138342 |
| Pegylated liposomal DOX (PLD) | Combined with albumin-bound PTX and trastuzumab | HER-2 positive BC | Oct. 2019 | I/II | To evaluate the efficacy and safety of PLD plus Albumin-Bound PTX and trastuzumab as neoadjuvant therapy in HER-2 positive BC | NCT03994107 |
| Abraxane® | Combined with CPT | TNBC | Dec. 2019 | III | This trial will compare the therapeutic effect of albumin-bound PTX with solvent-based PTX in TNBC patients, and seek for important scientific clues, scientific evidence, and clinical data for nab-P in the treatment of TNBC | NCT04137653 |
| PTX liposome | Combined with S-1 | Advanced PC | Jan. 2020 | IV | To investigate the efficacy and safety of the patients with confirmed advanced PC after treating with the combination of PTX liposome plus S-1 | NCT04217096 |
| Abraxane® | Combined with Alpelisib | TNBC | Feb. 2020 | II | To determine if alpelisib in combination with nab-PTX will improve treatment effect of patients with chemotherapy insensitive TNBC | NCT04216472 |
| Liposomal irinotecan (nal-IRI) | Combined with Oxaliplatin, Leucovorin, and 5-Fu | Locally Advanced Pancreatic Carcinoma (LAPC) | Mar. 2020 | II | To investigate the efficacy and tolerability of a combination of liposomal irinotecan (nal-IRI) with oxaliplatin, leucovorin, and 5-Fu (FOLFOX-nal-IRI) for treatment of patients with LAPC | NCT03861702 |
| Liposome-entrapped mitoxantrone hydrochloride injection (PLM60) | Monotherapy | Advanced HCC | Apr. 2020 | I | To evaluate the safety and efficacy of PLM60 in advanced HCC | NCT04331743 |
| NanoPac (sterile nanoparticulate PTX) powder for suspension | Monotherapy | SCLC | May 2020 | II | To evaluate the use of NanoPac injected directly into tumors in the lung of people with lung cancer | NCT04314895 |
Data were gathered by searching the National Institutes of Health (NIH)’s Clinical Trials.gov database at https://clinicaltrials.gov/. This table includes information on clinical trials as of 19 May 2020.